AC Immune (ACIU) investor relations material

Strategic focus and pipeline overview

• Precision prevention approach targets neurodegenerative diseases with active immunotherapies and small molecules.

• Pipeline includes candidates for Alzheimer's and Parkinson's diseases, with multiple assets in clinical phases and partnerships with major pharma companies.

• Over CHF 4.3 billion in potential milestones from strategic partnerships; cash reserves of CHF 91.4 million fund operations through Q3 2027.

• Four core value drivers: anti-pTau, anti-Abeta, anti-a-syn, and intracellular targeting programs.

Parkinson's disease program (ACI-7104.056)

• ACI-7104.056 is an active immunotherapy targeting pathological alpha-synuclein in early-stage Parkinson's disease.

• Phase 2 VacSYn study shows robust antibody response, good safety/tolerability, and stabilization of disease biomarkers.

• Treatment group exhibited stable neurofilament light chain and dopamine transporter imaging, suggesting slowed neurodegeneration.

• Motor symptom progression was limited in the treatment arm compared to placebo.

• Results support further development and regulatory discussions for registration.

Alzheimer's disease programs (ACI-35.030 and ACI-24.060)

• ACI-35.030, partnered with Janssen, is the only active immunotherapy in a prevention study for pre-symptomatic Alzheimer's; Phase 2b trial ongoing in ~500 patients.

• ACI-35.030 demonstrated significant reduction in plasma pTau217 and strong antibody responses.

• ACI-24.060 targets Abeta in Alzheimer's and Down syndrome; Phase 1b/2 ABATE study shows dose-dependent immune response and favorable safety profile.

• Preclinical data for ACI-24 show significant Abeta plaque reduction comparable to leading therapies.